NVO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk shares fall over 25% as Lilly gains ground
Eli Lilly is gaining ground in the obesity drug market, challenging Novo Nordisk’s position. Increased competition, U.S. pricing pressure and...
Eli Lilly's Foundayo Wins EU Panel Backing for Weight Loss, Diabetes
An expert panel for the European Union’s drug regulator has recommended marketing authorization for Eli Lilly’s weight-loss pill, Foundayo (orforglipron). The...
Novo Nordisk Shares Rise as GLP-1 Study Finds Fewer Psychiatric Hospitalizations
Novo Nordisk shares climbed after a study published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who received GLP-1...
WHO issues first childhood obesity guidelines, potentially impacting Novo Nordisk's market
The World Health Organization (WHO) released its first-ever guidelines for childhood and adolescent obesity. The WHO emphasizes lifestyle interventions, such...
FDA Review of Denecimig for Hemophilia A Extended Due to Manufacturing Issues
Novo Nordisk's denecimig, a hemophilia A treatment, faces an ongoing U.S. FDA review. The delay stems from unresolved manufacturing facility requirements. Novo...
Regeneron Drug Cuts Muscle Loss When Paired With Novo Nordisk's Semaglutide
In a mid-stage trial, Regeneron’s experimental drug trevogrumab, combined with Novo Nordisk’s semaglutide, reduced muscle loss associated with weight loss....
Novo Nordisk Links CagriSema Brain Changes to Substantial Weight Loss
Novo Nordisk presented new data on its investigational weight-management drug CagriSema at the European Association for the Study of Diabetes (EASD) Annual...
Novo Nordisk Finds Ozempic Linked to 6% Lower Heart Risk vs. Mounjaro
Novo Nordisk said a real-world analysis of more than 630,000 adults with type 2 diabetes found that Ozempic (semaglutide) at a 2 mg dose was associated with a...
Novo Nordisk Licenses Hengrui's Experimental Oral Obesity Drug for Up to $2.6B
Novo Nordisk has secured an exclusive license to develop HRS-1596, an experimental oral drug from China’s Jiangsu Hengrui Pharmaceuticals, for obesity and type...
Viatris Sues to Clear Path for Generic Wegovy
Viatris’s Mylan unit filed a lawsuit in a Delaware federal court seeking to market a generic version of Novo Nordisk’s Wegovy. It asks the court to rule that...
Novo Nordisk strikes $1.3B deal, targeting monthly obesity injections
Novo Nordisk entered a global exclusive license and collaboration agreement with Swedish firm Nanexa. The deal for Nanexa’s PharmaShell drug-delivery...
Novo Nordisk Eyes Direct NYSE Listing, Following Weight-Loss Drug Success
Novo Nordisk is considering a direct listing on the New York Stock Exchange to replace its American Depositary Receipts (ADRs). The company's CEO told the...
Novo Nordisk eyes acquisitions for weight-loss drugs, facing rising competition
Novo Nordisk CEO Mike Doustdar announced the company is seeking external acquisitions to bolster its weight-loss drug pipeline. The strategy targets assets...
Novo Nordisk Outperforms Eli Lilly, CagriSema Leads with 12.4% Weight Loss
Novo Nordisk’s experimental drug CagriSema outperformed Eli Lilly’s tirzepatide in a late-stage trial for type 2 diabetes. In the REIMAGINE 5 head-to-head...
🔴 Novo Nordisk is trading 6% down today after Capital Markets Day raises growth concerns
Novo Nordisk is trading 5.76% down now at $40.61 as its September 21, 2026 Capital Markets Day raises investor concerns about the company’s growth outlook. -...
Novo Nordisk Drops 6% as Investors Brace for Strategy Day: Can Management Convince the Market Its Best Days Aren't Behind It
Novo Nordisk Sinks 6% on Strategy Day Jitters: Can a Rebranded Company Outrun a Shrinking Growth Story Shares plunged 6.1% to $40.58 as Novo Nordisk — now...
🔴 Novo Nordisk is trading 6.2% down in pre-market as investors seek clearer growth plans beyond Wegovy
Novo Nordisk is trading 6.2% down now at $40.58 (-6.15%) as investors seek clearer plans to restore growth beyond Wegovy and compete with Eli Lilly. •...
🟢 Novo Nordisk is trading 4.05% up today after CHMP recommended Frehemgo EU authorisation
Novo Nordisk is trading 4.05% up now at $43.40 after the EMA’s CHMP recommended EU marketing authorisation for Frehemgo, its haemophilia A treatment. - The...
Novo Nordisk Wins EU Recommendation for Frehemgo, Reducing Hemophilia Bleeding
The European Medicines Agency’s CHMP recommended approval for Novo Nordisk’s hemophilia A therapy, Frehemgo (denecimig). The endorsement covers treatment for...
Novo Nordisk signs $1.4 billion Orbis deal, replacing injectable heart drugs
Novo Nordisk entered a strategic drug discovery and licensing agreement with Orbis Medicines worth up to $1.4 billion. The collaboration focuses on developing...